Literature DB >> 35111648

The diagnostic performance of whole-body MRI in the staging of lymphomas in adult patients compared to PET/CT and enhanced reference standard-systematic review and meta-analysis.

Lukas Lambert1, Andrea Burgetova1, Marek Trneny2, Bianka Bircakova1, Jan Molinsky2, Katerina Benesova2, David Zogala3, Pavel Michalek4.   

Abstract

BACKGROUND: Morphology highlighted by diffusion weighted imaging (DWI) is the basis of whole-body MRI (wbMRI). The aim of this study was to analyze current knowledge on the diagnostic performance of wbMRI in the pretreatment staging of patients with lymphoma.
METHODS: A search for original articles reporting the diagnostic performance (sensitivity, specificity) of pretreatment (first staging or staging in relapsed patients after complete remission) wbMRI in nodal and extranodal involvement by extracranial lymphoma and the agreement of stage by the Cotswolds-modified Ann Arbor classification in adult patients compared to the reference standard (PET/CT or enhanced reference standard) was conducted in PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov.
RESULTS: Altogether 15 studies with 519 patients were included in the meta-analysis. The pooled sensitivity and specificity for nodal involvement were 0.93 (95% CI: 0.90 to 0.96) and 0.99 (95% CI: 0.98 to 1.00). For nodal staging, most studies used the size criterion of 10 mm in the short diameter (n=10) and the absence of prominent fatty hilum (n=4). Restricted diffusion on diffusion-weighted imaging as a sign of nodal involvement was either not used (n=5), used for detection (n=4), semi-quantitatively (n=4), or quantitatively (n=1). Only one study (7) relied solely on restricted diffusion as the main criterion for nodal involvement. The pooled sensitivity and specificity for extranodal involvement were 0.89 (95% CI: 0.79 to 0.98) and 0.99 (95% CI: 0.99 to 1.00). Seven studies considered diffuse splenic involvement when its long or vertical axis was greater than 13 cm regardless of the patient's physiognomy. The pooled agreement in staging (Cohen's kappa) was almost perfect (0.90, 95% CI: 0.84 to 0.95). DISCUSSION: The sensitivity and specificity of wbMRI in the assessment of the nodal and extranodal involvement by lymphoma is high. The agreement of wbMRI with the reference standard is almost perfect. 2022 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  Lymphoma; PET/CT; agreement; meta-analysis; staging; whole-body MRI (wbMRI)

Year:  2022        PMID: 35111648      PMCID: PMC8739096          DOI: 10.21037/qims-21-649

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  26 in total

1.  Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.

Authors:  Henriëtte M E Quarles van Ufford; Thomas C Kwee; Frederik J Beek; Maarten S van Leeuwen; Taro Takahara; Rob Fijnheer; Rutger A J Nievelstein; John M H de Klerk
Journal:  AJR Am J Roentgenol       Date:  2011-03       Impact factor: 3.959

2.  Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.

Authors:  Jing Gu; Tao Chan; Jingbo Zhang; Anskar Y H Leung; Yok-Lam Kwong; Pek-Lan Khong
Journal:  AJR Am J Roentgenol       Date:  2011-09       Impact factor: 3.959

3.  Comparison of whole-body MRI with diffusion-weighted imaging and PET/CT in lymphoma staging.

Authors:  Siarhei Kharuzhyk; Edward Zhavrid; Andrei Dziuban; Elena Sukolinskaja; Olga Kalenik
Journal:  Eur Radiol       Date:  2020-02-27       Impact factor: 5.315

4.  Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.

Authors:  Cristina Ferrari; Carla Minoia; Artor Niccoli Asabella; Adriano Nicoletti; Corinna Altini; Filippo Antonica; Michele Ficco; Attilio Guarini; Nicola Maggialetti; Giuseppe Rubini
Journal:  Hell J Nucl Med       Date:  2014 Jan-Apr       Impact factor: 1.102

5.  Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.

Authors:  Domenico Albano; Caterina Patti; Ludovico La Grutta; Francesco Agnello; Emanuele Grassedonio; Antonino Mulè; Giorgio Cannizzaro; Umberto Ficola; Roberto Lagalla; Massimo Midiri; Massimo Galia
Journal:  Eur J Radiol       Date:  2015-12-12       Impact factor: 3.528

6.  Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas.

Authors:  Velasco Stéphane; Burg Samuel; Delwail Vincent; Guilhot Joelle; Perdrisot Remy; Guilhot Gaudeffroy Francois; Tasu Jean-Pierre
Journal:  Eur J Radiol       Date:  2013-08-09       Impact factor: 3.528

Review 7.  Lymphoma: Diagnosis and Treatment.

Authors:  William D Lewis; Seth Lilly; Kristin L Jones
Journal:  Am Fam Physician       Date:  2020-01-01       Impact factor: 3.292

Review 8.  Multimodality imaging of indolent B cell lymphoma from diagnosis to transformation: what every radiologist should know.

Authors:  Francesco Alessandrino; Pamela J DiPiro; Jyothi P Jagannathan; Gosangi Babina; Katherine M Krajewski; Nikhil H Ramaiya; Angela A Giardino
Journal:  Insights Imaging       Date:  2019-02-22

9.  Whole-body diffusion-weighted MRI in lymphoma-comparison of global apparent diffusion coefficient histogram parameters for differentiation of diseased nodes of lymphoma patients from normal lymph nodes of healthy individuals.

Authors:  Ricardo Donners; Raphael Shih Zhu Yiin; Dow-Mu Koh; Katja De Paepe; Ian Chau; Sue Chua; Matthew D Blackledge
Journal:  Quant Imaging Med Surg       Date:  2021-08

10.  Whole-body MRI versus 18F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis.

Authors:  Danyang Wang; Yanlei Huo; Suyun Chen; Hui Wang; Yingli Ding; Xiaochun Zhu; Chao Ma
Journal:  Onco Targets Ther       Date:  2018-06-20       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.